A large body of evidence from CVOTs in T2D has demonstrated cardiovascular and renal benefits when SGLT2-i were investigated, as well as benefits in people with heart failure [21,25,116,117,118,119,120]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.